Illumina, Inc. (NASDAQ:ILMN) Director Robert S. Epstein sold 1,346 shares of the stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $345.14, for a total transaction of $464,558.44. Following the completion of the sale, the director now owns 7,139 shares of the company’s stock, valued at approximately $2,463,954.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ILMN opened at $352.32 on Wednesday. The stock has a market cap of $50.72 billion, a P/E ratio of 88.08, a P/E/G ratio of 2.86 and a beta of 0.97. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.74 and a quick ratio of 2.44. Illumina, Inc. has a fifty-two week low of $196.00 and a fifty-two week high of $357.93.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.32. The company had revenue of $830.00 million during the quarter, compared to analyst estimates of $786.88 million. Illumina had a net margin of 20.88% and a return on equity of 26.64%. The firm’s revenue for the quarter was up 25.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.82 earnings per share. analysts predict that Illumina, Inc. will post 5.46 earnings per share for the current year.

ILMN has been the subject of several analyst reports. Bank of America increased their target price on shares of Illumina from $345.00 to $370.00 and gave the company a “buy” rating in a report on Tuesday, July 31st. BidaskClub downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Deutsche Bank increased their target price on shares of Illumina from $280.00 to $330.00 and gave the company a “buy” rating in a report on Tuesday, July 31st. Citigroup increased their target price on shares of Illumina from $330.00 to $345.00 and gave the company a “buy” rating in a report on Tuesday, July 31st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $340.00 target price (up previously from $330.00) on shares of Illumina in a report on Friday, July 27th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Illumina has a consensus rating of “Buy” and a consensus price target of $308.25.

A number of institutional investors and hedge funds have recently bought and sold shares of ILMN. Kaizen Advisory LLC grew its position in Illumina by 161.0% during the second quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock valued at $103,000 after buying an additional 227 shares during the period. Moneta Group Investment Advisors LLC grew its position in Illumina by 2,670.0% during the second quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after buying an additional 9,345 shares during the period. Sun Life Financial INC boosted its position in Illumina by 152.5% during the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock worth $111,000 after purchasing an additional 241 shares during the period. Harvest Fund Management Co. Ltd bought a new position in Illumina during the first quarter worth about $113,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in Illumina by 3,192.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock worth $120,000 after purchasing an additional 415 shares during the period. Institutional investors own 89.83% of the company’s stock.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Recommended Story: Investing in Growth Stocks

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.